Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study — Andrew X. Zhu (2014) | RDL Network
Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study
Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia‐Jui Yen, Kuan‐Der Lee, Ling Yang, Ian Chau
Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia-Jui Yen, Kuan‐Der Lee, Shao-Chun Chang, Ling Yang, Paolo Abada, Ian Chau
Josep M. Llovet, Chia‐Jui Yen, Richard S. Finn, Yoon‐Koo Kang, Masatoshi Kudo, Peter R. Galle, Éric Assenat, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Christophe Borg, Jean‐Baptiste Hiriart, Bruno Daniele, Thomas Berg, Hyun Cheol Chung, N Godinot, Chunxiao Wang, Yanzhi Hsu, William R. Schelman, Andrew X. Zhu
Discussion(0)
No comments yet. Be the first to comment.